0001209191-17-053004.txt : 20170915
0001209191-17-053004.hdr.sgml : 20170915
20170915164300
ACCESSION NUMBER: 0001209191-17-053004
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20170913
FILED AS OF DATE: 20170915
DATE AS OF CHANGE: 20170915
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Nielsen Ulrik B.
CENTRAL INDEX KEY: 0001531962
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-35409
FILM NUMBER: 171088373
MAIL ADDRESS:
STREET 1: MERRIMACK PHARMACEUTICALS, INC.
STREET 2: ONE KENDALL SQUARE, SUITE B7201
CITY: CAMBRIDGE
STATE: MA
ZIP: 02139
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: MERRIMACK PHARMACEUTICALS INC
CENTRAL INDEX KEY: 0001274792
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 000000000
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: ONE KENDALL SQUARE
STREET 2: SUITE B7201
CITY: CAMBRIDGE
STATE: MA
ZIP: 02139
BUSINESS PHONE: 617-441-1000
MAIL ADDRESS:
STREET 1: ONE KENDALL SQUARE
STREET 2: SUITE B7201
CITY: CAMBRIDGE
STATE: MA
ZIP: 02139
4
1
doc4.xml
FORM 4 SUBMISSION
X0306
4
2017-09-13
0
0001274792
MERRIMACK PHARMACEUTICALS INC
MACK
0001531962
Nielsen Ulrik B.
C/O MERRIMACK PHARMACEUTICALS, INC.
ONE KENDALL SQUARE, SUITE B7201
CAMBRIDGE
MA
02139
1
0
0
0
Common Stock
2017-09-14
4
M
0
100
13.20
A
22781
D
Common Stock
2017-09-14
4
S
0
100
14.20
D
22681
D
Common Stock
2017-09-15
4
M
0
7133
13.20
A
29814
D
Common Stock
2017-09-15
4
M
0
663
13.20
A
30477
D
Common Stock
2017-09-15
4
S
0
7796
14.23
D
22681
D
Stock Option (right to buy)
13.99
2017-09-13
4
A
0
7500
0.00
A
2027-09-12
Common Stock
7500
7500
D
Stock Option (right to buy)
13.20
2017-09-14
4
M
0
100
0.00
D
2017-10-04
Common Stock
100
7133
D
Stock Option (right to buy)
13.20
2017-09-15
4
M
0
7133
0.00
D
2017-10-04
Common Stock
7133
0
D
Stock Option (right to buy)
13.20
2017-09-15
4
M
0
663
0.00
D
2017-10-04
Common Stock
663
0
D
This option is fully vested.
This option was previously reported as covering 3,378 shares of common stock at an exercise price of $2.59 per share, but was adjusted to reflect both the special cash dividend that was payable on May 26, 2017 and the reverse stock split that became effective for trading purposes on September 6, 2017.
/s/ Brian J. Kickham, attorney-in-fact
2017-09-15